High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure
Top Cited Papers
Open Access
- 1 March 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Heart Failure
- Vol. 4 (2), 180-187
- https://doi.org/10.1161/circheartfailure.110.958223
Abstract
Background—: Soluble ST2 reflects activity of an interleukin-33–dependent cardioprotective signaling axis and is a diagnostic and prognostic marker in acute heart failure. The use of ST2 in chronic heart failure has not been well defined. Our objective was to determine whether plasma ST2 levels predict adverse outcomes in chronic heart failure in the context of current approaches. Methods and Results—: We determined the association between ST2 level and risk of death or transplantation in a multicenter, prospective cohort of 1141 chronic heart failure outpatients. Adjusted Cox models, receiver operating characteristic analyses, and risk reclassification metrics were used to assess the value of ST2 in predicting risk beyond currently used factors. After a median of 2.8 years, 267 patients (23%) died or underwent heart transplantation. Patients in the highest ST2 tertile (ST2 >36.3 ng/mL) had a markedly increased risk of adverse outcomes compared with the lowest tertile (ST2 ≤22.3 ng/mL), with an unadjusted hazard ratio of 3.2 (95% confidence interval [CI], 2.2 to 4.7; P P =0.002). In receiver operating characteristic analyses, the area under the curve for ST2 was 0.75 (95% CI, 0.69 to 0.79), which was similar to N-terminal pro-B–type natriuretic peptide (NT-proBNP) (area under the curve, 0.77; 95% CI, 0.72 to 0.81; P =0.24 versus ST2) but lower than the Seattle Heart Failure Model (area under the curve, 0.81 (95% CI, 0.77 to 0.85; P =0.014 versus ST2). Addition of ST2 and NT-proBNP to the Seattle Heart Failure Model reclassified 14.9% of patients into more appropriate risk categories ( P =0.017). Conclusions—: ST2 is a potent marker of risk in chronic heart failure and when used in combination with NT-proBNP offers moderate improvement in assessing prognosis beyond clinical risk scores.Keywords
This publication has 30 references indexed in Scilit:
- Serum Soluble ST2: A Potential Novel Mediator in Left Ventricular and Infarct Remodeling After Acute Myocardial InfarctionJournal of the American College of Cardiology, 2010
- Heart Disease and Stroke Statistics—2009 UpdateCirculation, 2009
- Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart FailureJournal of the American College of Cardiology, 2008
- The IL-33/ST2 pathway: therapeutic target and novel biomarkerNature Reviews Drug Discovery, 2008
- Biomarkers in Heart FailureThe New England Journal of Medicine, 2008
- Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial InfarctionCirculation, 2008
- Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea: Results From the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) StudyJournal of the American College of Cardiology, 2007
- IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling systemJCI Insight, 2007
- Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial InfarctionCirculation, 2004
- Heart FailureThe New England Journal of Medicine, 2003